genOway Stock OTC Markets

GWYNF

FR0004053510

Biotechnology & Medical Research

Delayed OTC Markets			5-day change	1st Jan Change
- ^USD	-.--%		-.--%	-

03-30	GenOway Société anonyme Reports Earnings Results for the Full Year Ended December 31, 2025	CI
12-31	GenOway Société anonyme completed the acquisition of Data Science and AI assets in OMICS platform.	CI

Analysts' recommendations: genOway

22/11/23	GenOway: sharp rise, broker initiates buy recommendation
22/11/23	GenOway: Euroland initiates buy coverage

More recommendations

News in other languages: genOway

07-15	Genoway dégage 10,9 MEUR de revenus au 1er semestre 2026
07-15	Genoway : Revenus totaux de 10,9 M EUR au 1er semestre 2026 - Accélération de la croissance visée au 2nd semestre
07-02	GenOway : 20260630 Bilan semestriel du contrat de liquidité - Juin 2026
06-19	Agenda des dividendes et des AG de la semaine : session dividendes pour la galaxie Bolloré
06-03	GenOway : 20260626 Avis de convocation

More news

Managers and Directors: genOway

Manager	Title	Age	Since
Christian Grenier CEO	Chief Executive Officer	-	-
Alexandre Fraichard COO	Chief Operating Officer	-	01/03/1999
Benjamin Bruneau DFI	Director of Finance/CFO	-	01/10/2015

Director	Title	Age	Since
Alexandre Fraichard BRD	Director/Board Member	-	01/03/1999
Christian Grenier CHM	Chairman	-	-
Laurent Fraisse BRD	Director/Board Member	-	-

More insiders

Other Biotechnology & Medical Research

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
GENOWAY	-.--%	-.--%	-	-	26.22M
LONZA GROUP AG	+0.11%	+2.71%	+0.44%	+26.85%	46.28B
IQVIA HOLDINGS INC.	-1.12%	+1.78%	+42.30%	+29.70%	43.85B
REVOLUTION MEDICINES, INC.	-3.04%	-6.29%	+338.56%	+542.28%	40.93B
BEONE MEDICINES AG	-0.74%	+1.25%	+4.92%	+81.93%	39.89B
CELLTRION, INC.	-0.50%	+0.67%	+10.29%	+41.28%	29.5B
MEDPACE HOLDINGS, INC.	-0.46%	+4.22%	+22.81%	+140.41%	17.09B
ASCENDIS PHARMA A/S	-0.97%	-10.17%	-	-	15.55B
EUROFINS SCIENTIFIC SE	-0.57%	+8.12%	+22.19%	+36.16%	15.22B
TEMPUS AI, INC.	-3.14%	+31.91%	-11.79%	-	14.05B
Average	-1.04%	+2.50%	+53.72%	+128.37%	29.15B
Weighted average by Cap.	-1.10%	+0.98%	+68.04%	+138.23%

See all sector performances

genOway est une société de biotechnologie spécialisée dans la conception et le développement de modèles de recherche moléculaires, cellulaires et animaux à forte valeur ajoutée pour les industries biopharmaceutique, chimique, agrochimique et agroalimentaire ainsi que pour la recherche académique. genOway est une société leader sur son marché. Elle appuie son développement sur la combinaison d'une large et exclusive plateforme technologique et d'une propriété intellectuelle forte combinant brevets et licences d'exploitation. genOway a conclu de nombreux contrats commerciaux avec les leaders de l'industrie pharmaceutique (BMS, Janssen, Novartis, Pfizer, etc.), et avec les centres de recherche académiques les plus prestigieux (King's College et Université de Manchester en Angleterre, Harvard, Caltech et le National Institute of Health aux Etats-Unis, l'Institut Pasteur en France, le NGFN et l'Institut Max Planck en Allemagne, etc.).

Employees

Sector

Biotechnology & Medical Research

More about the company

-40%: Exceptional extension

SEIZE THE OFFER!

Market Cap	22.87M 26.25M 21.59M 19.6M 36.73M 2.52B 36.86M 258M 99.79M 1.28B 98.58M 96.4M 4.12B	P/E 2024 *	-	P/E 2025	-
Enterprise Value	29.58M 33.96M 27.93M 25.36M 47.52M 3.26B 47.68M 334M 129M 1.66B 128M 125M 5.33B	EV / Sales 2024	1.28x	EV / Sales 2025	1.11x
Free-Float	59.02%	Yield 2024 *	-	Yield 2025	-

03-30	GenOway Société anonyme Reports Earnings Results for the Full Year Ended December 31, 2025	CI
12-31	GenOway Société anonyme completed the acquisition of Data Science and AI assets in OMICS platform.	CI
12-16	GenOway Société anonyme agreed to acquire Data Science and AI assets in OMICS platform for ?7 million.	CI
11-19	GenOway Soars 18% on Strong Momentum from Chinese Joint Venture
24/09/25	GenOway Société anonyme Reports Earnings Results for the Half Year Ended June 30, 2025	CI
27/03/25	GenOway Société anonyme Reports Earnings Results for the Full Year Ended December 31, 2024	CI
23/09/24	GenOway Société anonyme Reports Earnings Results for the Half Year Ended June 30, 2024	CI
19/07/24	GenOway: 15% growth in first-half sales
22/11/23	GenOway: sharp rise, broker initiates buy recommendation
22/11/23	GenOway: Euroland initiates buy coverage
17/10/23	GenOway: creation of a joint venture in Shanghai
22/09/23	GenOway: profitability target achieved ahead of schedule
21/09/23	GenOway Société anonyme Reports Earnings Results for the Half Year Ended June 30, 2023	CI

03-16	GenOway : 20250627 Avis de convocation	PU
11-18	Accélération du développement en Chine : la coentreprise genOway Shanghai devient un moteur clé de croissance pour le Groupe	PU
22/09/25	GenOway : Solides résultats semestriels 2025 avec une marge d’EBITDA à 16,9%	PU
27/03/24	GenOway : Résultats annuels 2023	PU
22/09/23	GenOway : Résultats du 1er semestre 2023	PU

	2024	2025
Net sales	27.53M 31.6M 25.99M 23.6M 44.22M 3.03B 44.38M 311M 120M 1.54B 119M 116M 4.96B	28.6M 32.83M 27M 24.52M 45.94M 3.15B 46.1M 323M 125M 1.6B 123M 121M 5.15B
Net income	1.83M 2.1M 1.73M 1.57M 2.94M 202M 2.95M 20.65M 7.99M 103M 7.89M 7.72M 330M	928K 1.06M 876K 795K 1.49M 102M 1.5M 10.47M 4.05M 51.98M 4M 3.91M 167M
Net Debt	623K 715K 588K 534K 1M 68.6M 1M 7.03M 2.72M 34.91M 2.69M 2.63M 112M	6.72M 7.71M 6.34M 5.76M 10.79M 740M 10.83M 75.78M 29.32M 376M 28.96M 28.32M 1.21B

genOway Stock OTC Markets

Stocks

GWYNF

FR0004053510

Biotechnology & Medical Research

Valuation: genOway

Latest news: genOway

Analysts' recommendations: genOway

Press Releases: genOway

News in other languages: genOway

Managers and Directors: genOway

Other Biotechnology & Medical Research

Financials

Company Profile